The University of Alabama at Birmingham (UAB) Comprehensive Cancer Center (CCC) has a long history of participation within the nation's cancer related Clinical Trials Cooperative Group Program. Specifically, UAB was a founding member of the GOG, and has been a member of RTOG, ECOG, ACRIN. CALGB, NSABP, and SWOG. The UAB CCC now submits this proposal to become a Lead Academic Participating Site, specifically named the NCTN Deep South Research Consortium, in the NCI's newly restructured National Clinical Trials Network (NCTN) Program. It is our intention to continue as a leading contributor of scientific leaders and clinical trial participants to the NCTN Program in th U.S. and particularly in the Southeast. To accomplish this overall vision, we propose the following specific aims: 1) To further enhance the involvement of existing UAB CCC scientific leadership in NCTN Center related clinical and translational research and to develop the next generation of NCTN Center scientific leaders within the UAB CCC, and 2) To further refine a clinical trials process within the UAB CCC that optimizes accrual of potentially eligible cancer patients and patients at risk for cancer to NCTN Center clinical trials. We include in this proposa a detailed description of our NCI cooperative group scientific and patient accrual contributions and accomplishments, a leadership and organizational structure for our proposed Consortium, and how we intend to utilize existing UAB CCC infrastructure to achieve our aims. We also include a detailed description of our proposed Junior Investigator Recruitment and Mentoring Program.

Public Health Relevance

This proposal will ensure that the NCTN Program is provided better access to UAB CCC clinical and translational investigators with a broad interest in cancer prevention and control, cancer biology, and experimental therapeutics. Importantly, this proposal will also provide NCTN clinical trials better access to a patient population that based upon its demographics and socioeconomic status is distinct from other areas in the country.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA180855-04
Application #
9236167
Study Section
Special Emphasis Panel (ZCA1-GRB-P (O1))
Program Officer
Mooney, Margaret M
Project Start
2014-04-16
Project End
2019-02-28
Budget Start
2017-03-01
Budget End
2018-02-28
Support Year
4
Fiscal Year
2017
Total Cost
$497,800
Indirect Cost
$86,829
Name
University of Alabama Birmingham
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Barrington, David A; Champion, Macie L; Boitano, Teresa K L et al. (2018) Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic. Gynecol Oncol 149:337-340
Van Arsdale, Anne R; Arend, Rebecca C; Cossio, Maria J et al. (2018) Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma. Cancer Med 7:616-625
Leath 3rd, Charles A; Monk, Bradley J (2018) Twenty-first century cervical cancer management: A historical perspective of the gynecologic oncology group/NRG oncology over the past twenty years. Gynecol Oncol 150:391-397
Toboni, Michael D; Smith, Haller J; Bae, Sejong et al. (2018) Predictors of Unplanned Reoperation for Ovarian Cancer Patients From the National Surgical Quality Improvement Program Database. Int J Gynecol Cancer 28:1427-1431
Subramaniam, Akila; Blanchard, Christina T; Erickson, Britt K et al. (2018) Feasibility of Complete Salpingectomy Compared With Standard Postpartum Tubal Ligation at Cesarean Delivery: A Randomized Controlled Trial. Obstet Gynecol 132:20-27
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Toboni, Michael D; Smith, Haller J; Dilley, Sarah E et al. (2017) Malignant Brenner tumor associated with a germline BRCA2 mutation. Gynecol Oncol Rep 21:17-19
Qu, Xiaoyu; Othus, Megan; Davison, Jerry et al. (2017) Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials. Cancer 123:2472-2481
Phippen, N T; Secord, A A; Wolf, S et al. (2017) Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study. Gynecol Oncol 147:98-103
Truong, Minh Tam; Zhang, Qiang; Rosenthal, David I et al. (2017) Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiatio Int J Radiat Oncol Biol Phys 97:687-699

Showing the most recent 10 out of 52 publications